Skip to Main content Skip to Navigation

Utilisation de dérivés cellulaires d'origine cardiaque au cours de l’ischémie reperfusion et du remodelage post-ischémique

Abstract : Background: Ischemic heart disease is the first cause of death in western countries. Despite early reperfusion and improvement of medical care, myocardial infarction (MI) mortality remains constant. Therefore new treatments are desirable. Among those new treatments, heart derived cells (obtained from cardiac explants) are promising. Those cells are grown from cardiac explants which, in culture, will spontaneously self-organized in three-dimensional multicellular cluster named cardiospheres. When replated in adherent surface, those cardiospheres will yield to a population of single cells named cardiosphere-derived cells (CDCs). Allogenic CDCs have been shown to decrease infarct size both in convalescent MI (pre-clinical and clinical studies) and in ischemia-reperfusion. However several small animal studies suggest that 1. Cardiospheres may be more potent than CDCs and 2. CDC-secreted exosomes are likely to be the mediator of CDC effect and their injection may recapitulate the effect of CDCs. Nevertheless, no study has assessed the efficacy of cardiospheres and CDC-derived exosomes in a relevant pre-clinical large-animal model. We aim to compare the effect of cardiospheres, CDCs and CDC-derived exosomes in pig models of convalescent MI (adverse remodeling) and acute MI (ischemia reperfusion).Methods: First, delivery, optimal dose and safety will be optimized. Then, randomized placebo-controlled study will be performed to assess efficacy. For all studies, MI will be performed by balloon occlusion of the left anterior descending artery after the 1st diagonal. For the acute studies, pigs will be treated 30 minutes after reperfusion and followed for 48 hours. For the chronic studies, pigs will be treated 4 weeks after MI and followed for 4 additional weeks. Efficacy will be evaluated by histology (no-reflow and infarct size) for the acute studies and by MRI (scar size and left ventricular function) for the chronic studies.Expected results: we expect to confirm the results obtained in small animal models. Efficacy of cardiospheres may be better than CDCs, and exosomes should be at least as effective as CDCs but with a more favorable safety profile (especially immunological).
Document type :
Complete list of metadatas

Cited literature [288 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Wednesday, November 27, 2019 - 1:44:08 PM
Last modification on : Friday, November 29, 2019 - 4:17:27 PM


Version validated by the jury (STAR)


  • HAL Id : tel-02382836, version 1



Romain Gallet de Saint-Aurin. Utilisation de dérivés cellulaires d'origine cardiaque au cours de l’ischémie reperfusion et du remodelage post-ischémique. Médecine humaine et pathologie. Université Paris-Est, 2018. Français. ⟨NNT : 2018PESC0084⟩. ⟨tel-02382836⟩



Record views


Files downloads